ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,260,362 | -9.8% | 60,478 | +3.7% | 0.01% | -11.1% |
| Q2 2023 | $1,396,956 | +27.9% | 58,328 | +0.5% | 0.01% | +28.6% |
| Q1 2023 | $1,092,049 | +20.6% | 58,026 | +2.0% | 0.01% | +16.7% |
| Q4 2022 | $905,386 | -3.1% | 56,871 | -0.4% | 0.01% | -14.3% |
| Q3 2022 | $934,000 | +17.8% | 57,079 | +1.4% | 0.01% | +40.0% |
| Q2 2022 | $793,000 | -44.9% | 56,272 | -5.3% | 0.01% | -37.5% |
| Q1 2022 | $1,439,000 | -3.1% | 59,424 | -6.6% | 0.01% | +14.3% |
| Q4 2021 | $1,485,000 | +36.5% | 63,606 | -2.9% | 0.01% | +16.7% |
| Q3 2021 | $1,088,000 | -33.5% | 65,510 | -2.3% | 0.01% | 0.0% |
| Q2 2021 | $1,636,000 | +2456.2% | 67,067 | +2602.1% | 0.01% | – |
| Q1 2021 | $64,000 | -57.0% | 2,482 | -10.7% | 0.00% | -100.0% |
| Q4 2020 | $149,000 | +25.2% | 2,778 | -4.0% | 0.00% | 0.0% |
| Q3 2020 | $119,000 | -17.9% | 2,895 | -3.2% | 0.00% | 0.0% |
| Q2 2020 | $145,000 | -94.8% | 2,991 | -95.5% | 0.00% | -93.3% |
| Q1 2020 | $2,815,000 | -6.6% | 66,636 | -5.5% | 0.02% | +25.0% |
| Q4 2019 | $3,015,000 | +25.9% | 70,486 | +5.9% | 0.01% | +20.0% |
| Q3 2019 | $2,394,000 | +33.7% | 66,530 | -0.7% | 0.01% | +42.9% |
| Q2 2019 | $1,791,000 | -7.6% | 66,993 | -7.2% | 0.01% | 0.0% |
| Q1 2019 | $1,939,000 | +85.0% | 72,216 | +11.4% | 0.01% | +75.0% |
| Q4 2018 | $1,048,000 | -22.7% | 64,798 | -0.8% | 0.00% | 0.0% |
| Q3 2018 | $1,356,000 | +38.5% | 65,295 | +1.8% | 0.00% | +33.3% |
| Q2 2018 | $979,000 | +1858.0% | 64,119 | +2759.9% | 0.00% | – |
| Q1 2018 | $50,000 | -27.5% | 2,242 | -2.0% | 0.00% | – |
| Q4 2017 | $69,000 | +6.2% | 2,287 | -2.3% | 0.00% | – |
| Q2 2017 | $65,000 | -13.3% | 2,341 | +7.9% | 0.00% | – |
| Q1 2017 | $75,000 | +15.4% | 2,169 | -3.6% | 0.00% | – |
| Q4 2016 | $65,000 | -99.9% | 2,251 | 0.0% | 0.00% | – |
| Q3 2016 | $71,604,000 | -1.0% | 2,251 | +1.0% | 0.00% | – |
| Q2 2016 | $72,353,000 | -95.0% | 2,229 | -95.7% | 0.00% | -100.0% |
| Q1 2016 | $1,459,000,000 | -13.8% | 52,187 | +10.0% | 0.01% | -14.3% |
| Q4 2015 | $1,692,000,000 | +106853.2% | 47,457 | -0.8% | 0.01% | 0.0% |
| Q3 2015 | $1,582,000 | -99.9% | 47,858 | +0.8% | 0.01% | -12.5% |
| Q2 2015 | $1,988,546,000 | +21.3% | 47,482 | -5.6% | 0.01% | +14.3% |
| Q1 2015 | $1,639,896,000 | +3.4% | 50,319 | +0.7% | 0.01% | 0.0% |
| Q4 2014 | $1,586,293,000 | +23.4% | 49,962 | -3.8% | 0.01% | +16.7% |
| Q3 2014 | $1,285,613,000 | +9.5% | 51,923 | -0.1% | 0.01% | +20.0% |
| Q2 2014 | $1,173,776,000 | +0.4% | 51,960 | +8.1% | 0.01% | 0.0% |
| Q1 2014 | $1,169,519,000 | -1.3% | 48,069 | +1.4% | 0.01% | -16.7% |
| Q4 2013 | $1,185,151,000 | -8.8% | 47,425 | +0.3% | 0.01% | -14.3% |
| Q3 2013 | $1,299,111,000 | +5326.5% | 47,292 | +3485.4% | 0.01% | – |
| Q2 2013 | $23,940,000 | – | 1,319 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |